Preclinical models for neuroblastoma: establishing a baseline for treatment.
Standard
Preclinical models for neuroblastoma: establishing a baseline for treatment. / Teitz, Tal; Stanke, Jennifer J; Federico, Sara; Bradley, Cori L; Brennan, Rachel; Zhang, Jiakun; Johnson, Melissa D; Sedlacik, Jan; Inoue, Madoka; Zhang, Ziwei M; Frase, Sharon; Rehg, Jerold E; Hillenbrand, Claudia M; Finkelstein, David; Calabrese, Christopher; Dyer, Michael A; Lahti, Jill M.
in: PLOS ONE, Jahrgang 6, Nr. 4, 4, 2011, S. 19133.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Preclinical models for neuroblastoma: establishing a baseline for treatment.
AU - Teitz, Tal
AU - Stanke, Jennifer J
AU - Federico, Sara
AU - Bradley, Cori L
AU - Brennan, Rachel
AU - Zhang, Jiakun
AU - Johnson, Melissa D
AU - Sedlacik, Jan
AU - Inoue, Madoka
AU - Zhang, Ziwei M
AU - Frase, Sharon
AU - Rehg, Jerold E
AU - Hillenbrand, Claudia M
AU - Finkelstein, David
AU - Calabrese, Christopher
AU - Dyer, Michael A
AU - Lahti, Jill M
PY - 2011
Y1 - 2011
N2 - Preclinical models of pediatric cancers are essential for testing new chemotherapeutic combinations for clinical trials. The most widely used genetic model for preclinical testing of neuroblastoma is the TH-MYCN mouse. This neuroblastoma-prone mouse recapitulates many of the features of human neuroblastoma. Limitations of this model include the low frequency of bone marrow metastasis, the lack of information on whether the gene expression patterns in this system parallels human neuroblastomas, the relatively slow rate of tumor formation and variability in tumor penetrance on different genetic backgrounds. As an alternative, preclinical studies are frequently performed using human cell lines xenografted into immunocompromised mice, either as flank implant or orthtotopically. Drawbacks of this system include the use of cell lines that have been in culture for years, the inappropriate microenvironment of the flank or difficult, time consuming surgery for orthotopic transplants and the absence of an intact immune system.
AB - Preclinical models of pediatric cancers are essential for testing new chemotherapeutic combinations for clinical trials. The most widely used genetic model for preclinical testing of neuroblastoma is the TH-MYCN mouse. This neuroblastoma-prone mouse recapitulates many of the features of human neuroblastoma. Limitations of this model include the low frequency of bone marrow metastasis, the lack of information on whether the gene expression patterns in this system parallels human neuroblastomas, the relatively slow rate of tumor formation and variability in tumor penetrance on different genetic backgrounds. As an alternative, preclinical studies are frequently performed using human cell lines xenografted into immunocompromised mice, either as flank implant or orthtotopically. Drawbacks of this system include the use of cell lines that have been in culture for years, the inappropriate microenvironment of the flank or difficult, time consuming surgery for orthotopic transplants and the absence of an intact immune system.
KW - Animals
KW - Humans
KW - Disease Models, Animal
KW - Mice
KW - Gene Expression Regulation, Neoplastic
KW - Oligonucleotide Array Sequence Analysis
KW - Gene Expression Profiling
KW - Mice, Transgenic
KW - Genes, myc
KW - Immunohistochemistry/methods
KW - Neoplasm Transplantation
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Drug Screening Assays, Antitumor
KW - Nervous System Neoplasms/genetics/pathology
KW - Neuroblastoma/genetics/pathology
KW - Animals
KW - Humans
KW - Disease Models, Animal
KW - Mice
KW - Gene Expression Regulation, Neoplastic
KW - Oligonucleotide Array Sequence Analysis
KW - Gene Expression Profiling
KW - Mice, Transgenic
KW - Genes, myc
KW - Immunohistochemistry/methods
KW - Neoplasm Transplantation
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Drug Screening Assays, Antitumor
KW - Nervous System Neoplasms/genetics/pathology
KW - Neuroblastoma/genetics/pathology
M3 - SCORING: Journal article
VL - 6
SP - 19133
JO - PLOS ONE
JF - PLOS ONE
SN - 1932-6203
IS - 4
M1 - 4
ER -